

MASSIMILIANO GNECCHI, MD, PhD, FESC

Medical Licence n 08082 Ordine dei Medici Chirurghi della Provincia di Pavia

Abilitazione nazionale Professore I fascia in Cardiologia

Business address: Fondazione IRCCS Policlinico San Matteo
Intensive Coronary Care Unit and Laboratory of Clinical and Experimental
Cardiology
Viale Golgi 19
27100 Pavia
(ITALY)

Nationality: Italian

Phone Number: +39-0382-982107

E-mail: massimiliano.gnecchi@unipv.it

POSITION AND EMPLOYMENT

03/2023 - present **Director of “Translational Cardiology”**
of the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

01/2019 – 03/2023 Position of High Specialization in Molecular and Translational Cardiology -
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

05/2018 - present Honorary Professor
Department of Medicine
University of Cape Town (South Africa)

11/2017 - present **Associate Professor of Cardiology**
Department of Molecular Medicine – Unit of Cardiology
University of Pavia – Pavia, Italy

11/2017 - present Faculty member of the PhD program in Translational Medicine
University of Pavia – Pavia, Italy

10/2012 - present Lecturer Faculty of Biotechnology
Cardio-Vascular Medicine Course
University of Pavia – Pavia, Italy

08/2012 – 04/2018 Visiting Senior Lecturer
Department of Medicine
University of Cape Town (South Africa)

01/2011 - present Attending physician
Intensive Coronary Care Unit
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

- 01/2011 - present Head "Laboratory of Experimental Cardiology for Cell and Molecular Therapy"
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 10/2010 - 10/2017 Assistant Professor of Cardiology (tenured position)
School of Cardiology
University of Pavia – Pavia, Italy
- 04/2006 - 03/2010 Research Assistant Professor of Cardiology (non-tenured position)
Faculty of Medicine,
University of Pavia – Pavia, Italy
- 03/2006 - 12/2010 Consultant Cardiologist
Intensive Coronary Care Unit
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 10/2004 - 2/2006 Research Associate,
Cardiovascular Research Laboratories,
Duke University Medical Center - Durham, NC, USA
- 09/2003 - 09/2004 Research Associate,
Cardiovascular Research Laboratories,
Brigham and Women's Hospital and Harvard Medical School – Boston, MA,
USA

EDUCATION AND TRAINING

October 2006 - October 2009

University of Pavia - Pavia, Italy
Faculty of Mathematics, Physics and Natural Sciences
PhD in Genetic and Biomolecular Sciences

September 2002 - September 2003

Cardiovascular Research Laboratories, Brigham and Women's Hospital and
Harvard Medical School, Boston, MA, USA
Research Fellowship

October 2002

Board Certification in Cardiology
School of Specialization in Cardiology
University of Pavia – Pavia, Italy
Faculty of Medicine and Surgery

June 1998

Medical Degree in Medicine and Surgery
Faculty of Medicine and Surgery
University of Pavia - Pavia, Italy

HONORS

- 2013** **Fellow** of the European Society of Cardiology
- 2011** **“Hot Topics in Cardiovascular Science”** at the American Heart Association Scientific Session 2011. Abstract selected as one of the three top-scoring works presented under the “Cardiac Regeneration/Cellular Therapy” category.
- 2010** **“Progetto di grande rilevanza Internazionale”**. Winner of an “Internationally Relevant Grant” from the Italian Ministry of Foreign Affairs. Dr. Gneccchi’s proposal was the only project selected for the category “stem cells”.
- 2008** **“Young Investigator Grant”**. Winner of a competitive grant from the Italian Ministry of Health; the project ranked in the top10 among 998 proposals.
- 2006** **Winner of National Research Award (“Programma Rientro dei Cervelli”)** from MIUR (Italian Ministry of University and Research). Prestigious competitive award and 4 years research grant.
- 2005** **Winner of the American College of Cardiology Young Investigator Award**. First prize in the category Molecular and Cellular Cardiology; finals held in Orlando, FL on March 8th, 2005, during the American College of Cardiology Annual Scientific Meeting.
- 2004** **Astra Zeneca Young Investigator Award**. Third prize in the category, Basic Science Research.
- 2002** **Società Italiana di Cardiologia Research Scholarship**. Winner of a competitive scholarship from the Società Italiana di Cardiologia (Italian Society of Cardiology) to support my research training in USA.

SCIENTIFIC SOCIETIES MEMBERSHIPS

- European Society of Cardiology (Fellow)
- International Society for Cell Therapy
- American Heart Association (AHA)
- Società Italiana di Cardiologia (SIC)

OFFICIAL POSITIONS WITHIN SCIENTIFIC SOCIETIES

European Society of Cardiology (ESC)

- 2024-26 Chairperson elected of the CARE Working group of the ESC
- 2021-present Member of Cellular Biology of the Heart Working Group of the ESC
- 2021-23 Member of the board of the Council of Basic Science of the ESC
- 2020-present Member of the nucleus of the CARE (Cardiovascular Regenerative & Reparative Medicine) Working Group of the ESC

International Society for Cell and Gene Therapy (ISCT).

- 2024-26 Chief Scientific Officer
- 2024-26 Member of the Board of Directors
- 2021-23 Vice President Europe of ISCT
- 2021-23 Member of the Board of Directors
- 2016-present Chair of the "Cardiovascular Committee" of the ISCT

Editorial board

International Journal of Cardiology
Cytotherapy

Reviewer for the following scientific journals

Lancet
Circulation
Circulation Research
Cardiovascular Research
European Heart Journal
European Journal of Heart Failure,
Journal of the American College of Cardiology
JACC Heart Failure
Stem Cells
Stem Cell Report
Journal of Molecular and Cell Cardiology
Plos One
Cytotherapy
International Journal of Cardiology

SYNTHETIC CLINICAL PROFILE

Prof. Gneccchi completed the Fellowship in Cardiology at the University of Pavia in 2002. During the years of the specialty Prof. Gneccchi worked at the Division of Cardiology and at the Coronary Intensive Care Unit of the IRCCS San Matteo Hospital of Pavia. During the last 18 months of his fellowship, Prof. Gneccchi worked at the Interventional Cardiology Unit of the IRCCS Policlinico San Matteo, performing about 500 coronary angiography and 250 percutaneous coronary procedures as first operator.

Since 2006, Prof. Gneccchi has been working at the Intensive Coronary Care Unit of the IRCCS San Matteo in Pavia where he deals with the treatment of patients affected by acute cardiovascular diseases such as acute myocardial infarction, acute and refractory heart failure, pulmonary embolism, malignant arrhythmias, valvulopathies, myocarditis, myo-pericarditis. The complexity of the patients admitted to the ICCU requires the in-depth knowledge of both cardiology and pharmacology, combined with a prompt decision-making attitude. The capacity to relate and work in a team of colleagues also from other disciplines is a key prerogative in an environment such as the ICCU.

Prof. Gneccchi also acts as consultant for the "Post myocardial infarction ambulatory" of the San Matteo Hospital, where risk stratification is carried out by multi-modality imaging and clinical tests. Prof. Gneccchi is the responsible for a prospective registry of all STEMI patients discharged by the San Matteo Hospital and of a National prospective registry of post STEMI patients aiming to establish the clinical and genetic predictors of ventricular fibrillation during the first myocardial infarction.

Dr. Gneccchi is familiar with ICH-GCP and has experience in performing clinical trials according to the ICH-GCP principles.

SYNTHETIC RESEARCH PROFILE

Between 2002 and 2006 Prof. Gneccchi worked in the United States, at the Brigham and Woman's Hospital & Harvard Medical School in Boston first and later at Duke University Medical Center, in the cardiovascular research laboratory directed by Prof. Victor J. Dzau, a world leader in cardiovascular research.

During the years spent in the United States, Prof. Gneccchi devoted himself to the study of stem cells as a possible therapy for cardiovascular diseases. In particular, using a combined approach of cell and gene therapy, Prof. Gneccchi was able to demonstrate, for the first time in the world, that mesenchymal stem cells perform a beneficial action on the myocardium mainly via paracrine, i.e. cytoprotective factors capable of preserving the viability of the ischemic myocardium present in the area at the periphery of the infarct. This new theory, first published in Nature Medicine and FASEB Journal, was later validated by the work of numerous other laboratories and the paracrine effect is currently considered the main mechanism of action of stem cells for the treatment not only of myocardial infarction but also of numerous other pathologies such as, for example, stroke, kidney and lung damage, peripheral vascular disease, muscle injuries and liver disease. The discovery of the paracrine effect has opened a whole new line of research based on the identification of mediators with a view to developing "cell free" therapies.

The pioneering work of Prof. Gneccchi is internationally recognized by experts in the field as evidenced by a citation index Scopus (January 2023) of 1425 for the work published in Nature Medicine and over 1000 for the work published in FASEB Journal, in addition to 1670 of a review on the same topic and published in 2008 in Circulation Research.

For his research on the paracrine effect of stem cells, in 2005 Prof. Gneccchi was awarded the prestigious ***Young Investigator Award from the American College of Cardiology***.

Also, in 2005, Prof. Gneccchi was the winner of the "Return of brains" competition launched by the Italian Ministry of University and Research and consequently returned to Italy in 2006 as non-tenure Assistant Professor in Cardiology the University of Pavia. It also stipulated a collaboration agreement with the IRCCS Policlinico San Matteo Foundation, where the "Laboratory of Experimental Cardiology for Cell and Molecular Therapy" was created and which Prof. Gneccchi has been directing continuously since 2006.

The main purpose of the research carried out by Prof. Gneccchi is to identify the identity of the cardio-protective factors released by stem cells and to test new therapeutic approaches on a molecular basis for the treatment of myocardial infarction and chronic heart failure with the aim of translating the treatment with cells to the patient's bed.

Prof. Gneccchi coordinates a research group of biologists, biotechnologists, pharmaceutical chemists, and medical doctors. His research group, in addition to paracrine effects, deals or has dealt with the following research topics:

- identification of experimental models to favor the differentiation of adult stem cells into cardiomyocytes;
- generation and use of cardiomyocytes derived from induced pluripotent stem cells (iPSC) for disease modelling and drug testing;
- study of new therapeutic approaches that combine the use of stem cells and biomaterials;
- identification of specific circulating miRNAs useful for the diagnosis and prognostic stratification of patients suffering from heart disease of various origins (acute myocardial infarction, heart failure, patients undergoing bi-ventricular pacemaker implantation);
- identification of pathophysiological mechanisms underlying cardiac dysfunction in patients affected by amyloidosis.

Prof. Gneccchi's research activity has been financed continuously since 2006 by grants from the following funding agencies: Italian Ministry of University and Research; Ministry of Health; Ministry of Foreign Affairs; Cariplo Foundation; Leducq Foundation, AIFA (total of over 4 million Euro).

Prof. Gneccchi also entertains MANY COLLABORATIONS WITH PRESTIGIOUS UNIVERSITIES AND RESEARCH INSTITUTES AT NATIONAL AND INTERNATIONAL LEVEL.

As evidence of internationally recognized scientific credibility, Prof. Gneccchi was awarded the position of Honorary Professor by the University of Cape Town in South Africa, where he coordinated a research project on combined use of stem cells and biomaterials funded by the Ministry of Foreign Affairs as part of the "Projects of great international importance". Another collaborative project on the use of iPSCs for the study of genetic diseases in the South African population is currently underway.

Other disease modeling studies based on the use of iPSCs have been conducted with the Universities of Munich (Germany), Milan, Singapore and Hong Kong and have led to important scientific publications. For the study of mesenchymal stem cells, there have been collaborations with the University of Groningen, and the Erasmus Center of Rotterdam in the Netherlands.

In addition to basic and translational research activities, Prof. Gneccchi has participated and is participating as co-investigator in randomized clinical studies, mainly in the field of ischemic heart disease and dyslipidemia.

Prof. Gneccchi is the PI of a prospective registry of STEMI patients discharged by the San Matteo Hospital. The analysis of this registry, that was started 15 years ago, has allowed to discover numerous predictive parameters of cardiovascular outcome in post ischemic patients and patients affected by chronic ischemic heart disease. Studies have been conducted on the adherence to therapy with statins, to the meaning of various biochemical parameters including inflammation and renal dysfunction parameters.

Prof. Gneccchi is also responsible for a National prospective registry of post-AMI patients aiming to establish the clinical and genetic predictors of ventricular fibrillation during a first myocardial infarction episode.

Prof. Gneccchi's competence and recognized position on the international scene in the field of cardiovascular research is testified not only by the scientific production of relevant quality and originality, but also by numerous invited readings he has held over the last 15 years (over 150).

Prof. Gneccchi was a member of the scientific committee organizing scientific congresses of international importance such as, for example, the annual congress of the International Society for Cell and Gene Therapy (ISCT) and of the European Society of Thoracic Surgeons.

TEACHING ACTIVITIES

- November 2017 – present Associate Professor in Cardiology
Department of Molecular Medicine – Unit of Cardiology
Faculty of Medicine and Surgery
University of Pavia
Teaching and tutoring:
- Integrated Course “Diseases of the Cardiovascular System”
Golgi Degree Course in Medicine and Surgery (in Italian);
 - Integrated Course “Diseases of the Cardiovascular System”
Harvey Degree Course in Medicine and Surgery (in English);
 - School of Specialization in Cardiology;
 - School of Specialization in Internal Medicine;
 - School of Specialization in Pulmonary Medicine;
 - School of Specialization in Cardiac Surgery;
 - School of Specialization in Anesthesiology and Reanimation;
 - School of Specialization in Radiology;
 - School of Specialization in Sport Medicine;
 - School of Specialization in Geriatric Medicine;
 - School of Specialization in Pathology and Clinical Biochemistry.
- August 2018 – present Honorary Professor
Department of Medicine
University of Cape Town (South Africa)
- April 2017 – present Member of the PhD Program in Translational Medicine,
Department of Molecular Medicine – Unit of Cardiology
Faculty of Medicine and Surgery
University of Pavia
- October 2010 – October 2017 Assistant Professor of Cardiology
Department of Molecular Medicine – Unit of Cardiology
Faculty of Medicine and Surgery
University of Pavia
Teaching and tutoring:
- Integrated Course “Diseases of the Cardiovascular System”
Golgi Degree Course in Medicine and Surgery (in Italian);
 - Integrated Course “Diseases of the Cardiovascular System”
Harvey Degree Course in Medicine and Surgery (in English);
 - School of Specialization in Cardiology;
- October 2012 – present Holder of the course of Cardiovascular System Diseases
Corso di Laurea in Biotecnologie presso l’Università di Pavia.
- August 2012 – present Visiting Senior Lecturer
Department of Medicine
University of Cape Town (South Africa)

April 2006 - March 2010

Non tenure track Assistant Professor of Cardiology
Department of Molecular Medicine – Unit of Cardiology
Faculty of Medicine and Surgery
University of Pavia

Teaching and tutoring:

- Integrated Course “Diseases of the Cardiovascular System”
Golgi Degree Course in Medicine and Surgery (in Italian);
- Integrated Course “Diseases of the Cardiovascular System”
Harvey Degree Course in Medicine and Surgery (in English);
- School of Specialization in Cardiology;

SELECTED PEER REVIEWED MANUSCRIPTS

1. Crotti L, Neves R, Dagradi F, Musu G, Giannetti F, Bos J, Barbieri M, Cerea P, Giovenzana F, Torchio M, Mura M, **Gnecchi M**, Conte G, Auricchio A, Sala L, Odening K, Ackerman M, Schwartz PJ.
Therapeutic efficacy of mexiletine for LQT2: Evidence from hiPSC-derived cardiomyocytes, transgenic rabbits and patients
Circulation 2024 In press
2. Sanchez-Guijo F, Vives J, Ruggeri A, Chabannon C, Corbacioglu S, Dolstra H, Farge D, Gagelmann N, Horgan C, Kuball J, Neven B, Rintala T, Rocha V, Sanchez-Ortega I, Snowden JA, Zwaginga JJ, **Gnecchi M**, Sureda A.
Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT).
Cytotherapy. 2024 Feb 17:S1465-3249(24)00054-9. doi: 10.1016/j.jcyt.2024.02.007.
3. Cornara S, Mandurino-Mirizzi A, Somaschini A, Mauri S, Crimi G, Munafò A, Camporotondo R, **Gnecchi M**, De Servi S, De Ferrari GM, Ferlini M.
Derivation and validation of the incomplete ST-segment resolution score and its usefulness for treatment with glycoprotein IIb-IIIa inhibitors
J Cardiovasc Med. 2024 Feb 1;25(2):173-175. doi: 10.2459/JCM.0000000000001583.
4. Somaschini A, Cornara S, Leonardi S, Demarchi A, Mandurino-Mirizzi A, Fortuni F, Ferlini M, Crimi G, Camporotondo R, **Gnecchi M**, Oltrona Visconti L, De Servi S, De Ferrari GM.
Beneficial Effects of IABP in Anterior Myocardial Infarction Complicated by Cardiogenic Shock
Medicina (Kaunas). 2023 Oct 11;59(10):1806. doi: 10.3390/medicina59101806.
5. Vives J, Sanchez-Guijo F, **Gnecchi M**, Zwaginga JJ.
Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe.
Cytotherapy. 2023 Jul 27:S1465-3249(23)00982-9. doi: 10.1016/j.jcyt.2023.06.006.
6. Giannetti F, Barbieri M, Shiti A, Casini S, Sager PT, Das S, Pradhananga S, Srinivasan D, Nimani S, Alerni N, Louradour J, Mura M, **Gnecchi M**, Brink P, Zehender M, Koren G, Zaza A, Crotti L, Wilde AAM, Schwartz PJ, Remme CA, Gepstein L, Sala L, Odening KE.
Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2.
Europace. 2023 May 19;25(5):euad094. doi: 10.1093/europace/euad094.
7. Evans PC, Davidson SM, Wojta J, Bäck M, Bollini S, Brittan M, Catapano AL, Chaudhry B, Cluitmans M, **Gnecchi M**, Guzik TJ, Hofer I, Madonna R, Monteiro JP, Morawietz H, Osto E, Padró T, Sluimer JC, Tocchetti CG, Van der Heiden K, Vilahur G, Waltenberger J, Weber C.
From novel discovery tools and biomarkers to precision medicine-basic cardiovascular science highlights of 2021/22.
Cardiovasc Res. 2022 Oct 21;118(13):2754-2767. doi: 10.1093/cvr/cvac114. (IF: 14,2)
8. Gyöngyösi M, Alcaide P, Asselbergs FW, Brundel BJJM, Camici GG, da Costa Martins P, Ferdinandy P, Fontana M, Girao H, **Gnecchi M**, Gollmann-Tepeköylü C, Kleinbongard P, Krieg T,

Madonna R, Paillard M, Pantazis A, Perrino C, Pesce M, Schiattarella GG, Sluijter JPG, Steffens S, Tschöpe C, Van Linthout S, Davidson SM.

Long COVID and the cardiovascular system - elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial & Pericardial Diseases.

Cardiovasc Res. 2022 Jul 25;cvac115. doi: 10.1093/cvr/cvac115. Online ahead of print. (IF: 14,2)

9. Vezzoli M, Inciardi RM, Oriecuia C, Paris S, Murillo NH, Agostoni P, Ameri P, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Danzi G, Dalla Vecchia L, Giovinazzo S, **Gnecchi M**, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Pagnesi M, Piepoli M, Porto I, Pozzi A, Provenzale G, Sarullo F, Senni M, Sinagra G, Tomasoni D, Adamo M, Volterrani M, Maroldi R, Metra M, Lombardi CM, Specchia C.J

Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study.

J Cardiovasc Med 2022 Jul 1;23(7):439-446. doi:

10.2459/JCM.0000000000001329.PMID: 35763764 (IF: 2,4)

10. **Gnecchi M.**

Self-perception of acute symptoms in adolescents with COVID-19.

Lancet Reg Health Eur. 2022 May;16:100383. doi: 10.1016/j.lanepe.2022.100383. (IF: 20,9)

11. Lombardi CM, Specchia C, Conforti F, Rovere MT, Carubelli V, Agostoni P, Carugo S, Danzi GB, Guazzi M, Mortara A, Piepoli M, Porto I, Sinagra G, Volterrani M, Ameri P, **Gnecchi M**, Leonardi S, Merlo M, Iorio A, Bellasi A, Canale C, Camporotondo R, Catagnano F, Dalla Vecchia LA, Di Pasquale M, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Nuzzi V, Oriecuia C, Pala L, Peveri G, Pozzi A, Provenzale G, Sarullo F, Adamo M, Tomasoni D, Inciardi RM, Senni M, Metra M.

Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study.

J Cardiovasc Med (Hagerstown). 2022 Apr 1;23(4):254-263. doi:

10.2459/JCM.0000000000001261. (IF: 2,4)

12. Iorio A, Lombardi CM, Specchia C, Merlo M, Nuzzi V, Ferraro I, Peveri G, Oriecuia C, Pozzi A, Inciardi

RM, Carubelli V, Bellasi A, Canale C, Camporotondo R, Catagnano F, Vecchia LD, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Provenzale G, Sarullo F, Tomasoni D, Ameri P, **Gnecchi M**, Leonardi S, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Volterrani M, Sinagra G, Senni M, Metra M.

Combined Role of Troponin and Natriuretic Peptides Measurements in Patients with Covid-19 (from the Cardio-COVID-Italy Multicenter Study).

Am J Cardiol. 2022 Jan 18:S0002-9149(21)01204-2. doi: 10.1016/j.amjcard.2021.11.054.

(IF=2,77)

13. Sala L, Leonov V, Mura M, Giannetti F, Khudiakov A, Moretti A, Crotti L, **Gnecchi M**, Schwartz PJ. ***Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19.*** Front Physiol. 2022 Jan 27;12:730127. doi: 10.3389/fphys.2021.730127. (IF=4,56)
14. Baldi E, Camporotondo R, **Gnecchi M**, Totaro R, Guida S, Costantino I, Repetto A, Savastano S, Sacchi MC, Bollato C, Giglietta F, Oltrona Visconti L, Leonardi S; STEACS-EMS study group. ***Barriers associated with emergency medical service activation in patients with ST-segment elevation acute coronary syndromes.*** Intern Emerg Med. 2021 Nov 26:1-10. doi: 10.1007/s11739-021-02894-7. Online ahead of print. (IF: 3,4)
15. Lima Correa B, El Harane N, Desgres M, Perotto M, Alayrac P, Guillas C, Pidial L, Bellamy V, Baron E, Autret G, Kamaleswaran K, Pezzana C, Perier MC, Vilar J, Alberdi A, Brisson A, Renault N, **Gnecchi M**, Silvestre JS, Menasché P. ***Extracellular vesicles fail to trigger the generation of new cardiomyocytes in chronically infarcted hearts.*** Theranostics. 2021 Nov 2;11(20):10114-10124. doi: 10.7150/thno.62304. eCollection 2021. (IF: 11,55)
16. Kozek K, Wada Y, Sala L, Denjoy I, Egly C, O'Neill MJ, Aiba T, Shimizu W, Makita N, Ishikawa T, Crotti L, Spazzolini C, Kotta MC, Dagradi F, Castelletti S, Pedrazzini M, **Gnecchi M**, Leenhardt A, Salem JE, Ohno S, Zuo Y, Glazer AM, Mosley JD, Roden DM, Knollmann BC, Blume JD, Extramiana F, Schwartz PJ, Horie M, Kroncke BM. ***Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants.*** Circ Genom Precis Med. 2021 Aug;14(4):e003289. doi: 10.1161/CIRCGEN.120.003289. (IF: 3,4)
17. Paris S, Inciardi RM, Lombardi CM, Tomasoni D, Ameri P, Carubelli V, Agostoni P, Canale C, Carugo S, Danzi G, Di Pasquale M, Sarullo F, La Rovere MT, Mortara A, Piepoli M, Porto I, Sinagra G, Volterrani M, **Gnecchi M**, Leonardi S, Merlo M, Iorio A, Giovinnazzo S, Bellasi A, Zaccone G, Camporotondo R, Catagnano F, Dalla Vecchia L, Maccagni G, Mapelli M, Margonato D, Monzo L, Nuzzi V, Pozzi A, Provenzale G, Specchia C, Tedino C, Guazzi M, Senni M, Metra M. ***Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study.*** Europace. 2021 Oct 9;23(10):1603-1611. doi: 10.1093/europace/euab146. (IF: 5,2)
18. Nuzzi V, Merlo M, Specchia C, Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, Camporotondo R, Catagnano F, Dalla Vecchia LA, Giovinnazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Oriecuia C, Peveri G, Pozzi A, Provenzale G, Sarullo F, Tomasoni D, Ameri P, **Gnecchi M**, Leonardi S, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Volterrani M, Senni M, Metra M, Sinagra G. ***The prognostic value of serial troponin measurements in patients admitted for COVID-19.*** ESC Heart Fail. 2021 Oct;8(5):3504-3511. doi: 10.1002/ehf2.13462. (IF: 3,9)
19. Pandolfi L, Bozzini S, Frangipane V, Percivalle E, De Luigi A, Violatto MB, Lopez G, Gabanti E, Carsana L, D'Amato M, Morosini M, De Amici M, Nebuloni M, Fossali T, Colombo R, Saracino L, Codullo V, **Gnecchi M**, Bigini P, Baldanti F, Lilleri D, Meloni F. ***Neutrophil Extracellular Traps Induce the Epithelial-Mesenchymal Transition: Implications in***

Post-COVID-19 Fibrosis.

Front Immunol. 2021 Jun 14;12:663303. doi: 10.3389/fimmu.2021.663303. eCollection 2021. (IF: 6,4)

20. Pagnesi M, Inciardi RM, Lombardi CM, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, **Gnecchi M**, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zacccone G, Senni M, Metra M.
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study.
Int J Infect Dis. 2021 Jul;108:270-273. doi: 10.1016/j.ijid.2021.05.056. (IF: 3,6)
21. Mandurino-Mirizzi A, Kajana V, Cornara S, Somaschini A, Demarchi A, Galazzi M, Crimi G, Ferlini M, Camporotondo R, **Gnecchi M**, Ferrario M, Oltrona-Visconti L, De Ferrari GM.
Elevated serum uric acid is a predictor of contrast associated acute kidney injury in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Nutr Metab Cardiovasc Dis. 2021 Jun 30;31(7):2140-2143. doi: 10.1016/j.numecd.2021.04.002. Epub 2021 Apr 19. (IF: 4,2)
22. **Gnecchi M**, Sala L, Schwartz PJ.
Precision Medicine and cardiac channelopathies: when dreams meet reality.
Eur Heart J. 2021 May 1;42(17):1661-1675. doi: 10.1093/eurheartj/ehab007.ADFSD (IF: 30)
23. Mandurino-Mirizzi A, Cornara S, Somaschini A, Demarchi A, Galazzi M, Puccio S, Montalto C, Crimi G, Ferlini M, Camporotondo R, **Gnecchi M**, Ferrario M, Oltrona-Visconti L, De Ferrari GM.
Elevated serum uric acid is associated with a greater inflammatory response and with short- and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Nutr Metab Cardiovasc Dis. 2021 Feb 8;31(2):608-614. doi: 10.1016/j.numecd.2020.10.020. Epub 2020 Nov 3. (IF: 4,2)
24. Demarchi A, Cornara S, Somaschini A, Fortuni F, Mandurino-Mirizzi A, Crimi G, Ferlini M, **Gnecchi M**, De Servi S, Visconti LO, De Ferrari GM.
Has hyperglycemia a different prognostic role in STEMI patients with or without diabetes?
Nutr Metab Cardiovasc Dis. 2021 Feb 8;31(2):528-531. doi: 10.1016/j.numecd.2020.09.005. Epub 2020 Sep 17. (IF: 4,2)
25. Avanzini MA, Mura M, Percivalle E, Bastaroli F, Croce S, Valsecchi C, Lenta E, Nykjaer G, Cassaniti I, Bagnarino J, Baldanti F, Zecca M, Comoli P, **Gnecchi M**.
Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection.
Stem Cells Transl Med. 2021 Apr;10(4):636-642. doi: 10.1002/sctm.20-0385. Epub 2021 Jan 26. (IF: 5,6)

26. Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, **Gnecchi M**, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Volterrani M, Zaccone G, Guazzi M, Senni M, Metra M.
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.
Eur J Heart Fail. 2020 Dec;22(12):2238-2247. doi: 10.1002/ejhf.2052. Epub 2020 Nov 27. (IF: 15,5)
27. Dusi V, Vitolo V, Frigerio L, Totaro R, Valentini A, Barcellini A, Mirandola A, Perego GB, Coccia M, Greco A, Ghio S, Valvo F, De Ferrari GM, **Gnecchi M**, Oltrona Visconti L, Rordorf R.
First-in-man case of non-invasive proton radiotherapy for the treatment of refractory ventricular tachycardia in advanced heart failure.
Eur J Heart Fail. 2021 Jan;23(1):195-196. doi: 10.1002/ejhf.2056. Epub 2020 Nov 25. (IF: 15,5)
28. Ameri P, Inciardi RM, Di Pasquale M, Agostoni P, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Danzi G, Dalla Vecchia L, Giovinazzo S, **Gnecchi M**, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Provenzale G, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zaccone G, Lombardi CM, Senni M, Metra M.
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study.
Clin Res Cardiol. 2021 Jul;110(7):1020-1028. doi: 10.1007/s00392-020-01766-y. (IF: 4,4)
29. Vicentini A, Masiello L, D'Amore S, Baldi E, Ghio S, Savastano S, Sanzo A, Di Matteo A, Seminari EM, Lenti MV, Bosio M, Petracci B, Frigerio L, Sabena A, Tavazzi G, Oltrona Visconti L, Rordorf R; **San Matteo COVID Cardiac Injury Task Force.**
QTc Interval and Mortality in a Population of SARS-2-CoV Infected Patients.
Circ Arrhythm Electrophysiol. 2020 Nov;13:e008890. doi: 10.1161/CIRCEP.120.008890. (IF: 4)
30. Ghio S, Baldi E, Vicentini A, Lenti MV, Di Sabatino A, Di Matteo A, Zuccaro V, Piloni D, Corsico A, **Gnecchi M**, Speciale F, Sabena A, Oltrona Visconti L, Perlini S; San Matteo COVID Cardiac Injury Task Force.
Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy.
Intern Emerg Med. 2020 Nov;15(8):1457-1465. doi: 10.1007/s11739-020-02493-y. (IF: 3,4)
31. Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, Camporotondo R, Catagnano F, Dalla Vecchia LA, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Nuzzi V, Oriecuia C, Peveri G, Pozzi A, Provenzale G, Sarullo F, Tomasoni D, Ameri P, **Gnecchi M**, Leonardi S, Merlo M, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Sinagra G, Volterrani M, Specchia C, Metra M, Senni M.
Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study.
JAMA Cardiol. 2020 Nov 1;5(11):1274-1280. doi: 10.1001/jamacardio.2020.3538. (IF: 14,7)

32. Cavagna L, Seminari E, Zanframundo G, Gregorini M, Di Matteo A, Rampino T, Montecucco C, Pelenghi S, Cattadori B, Pattonieri EF, Vitulo P, Bertani A, Sambataro G, Vancheri C, Biglia A, Bozzalla-Cassione E, Bonetto V, Monti MC, Ticozzelli E, Turco A, Oggionni T, Corsico A, Bertuccio F, Zuccaro V, Codullo V, Morosini M, Marena C, **Gnecchi M**, Pellegrini C, Meloni F.
Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.
Microorganisms. 2020 Jun 30;8(7):977. doi: 10.3390/microorganisms8070977. (IF: 4,1)
33. Casula M, Fortuni F, Fabris F, Leonardi S, **Gnecchi M**, Sanzo A, Greco A, Rordorf R.
Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis.
J Cardiovasc Med (Hagerstown) 2020 Aug;21(8):570-576. doi: 10.2459/JCM.0000000000001041. (IF: 1,3)
34. **Gnecchi M**, Fortuni F, Bassi EM, Leonardi S, Totaro R, Perotti L, Zuccaro V, Perlini S, Preda L, Baldanti F, Bruno R, Oltrona Visconti L.
Myocarditis in a 16-year-old boy positive for SARS-CoV-2.
Lancet. 2020 Jun 27;395(10242):e116. doi: 10.1016/S0140-6736(20)31307-6. (IF: 79,3)
35. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, Mancone M, Mercurio G, Muscoli S, Nodari S, Pedrinelli R, Sinagra G, Indolfi C; **Società Italiana di Cardiologia and the CCU Academy investigators group.**
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020 May 15:ehaa409. doi: 10.1093/eurheartj/ehaa409. Online ahead of print. (IF: 30)
36. Demarchi A, Mazzucchelli I, Somaschini A, Cornara S, Dusi V, Mirizzi AM, Ruffinazzi M, Crimi G, Ferlini M, **Gnecchi M**, Visconti LO, De Servi S, De Ferrari GM.
Leptin Affects the Inflammatory Response After STEMI.
Nutr Metab Cardiovasc Dis. 2020 Feb 21:S0939-4753(20)30052-1. doi: 10.1016/j.numecd.2020.02.004. (IF: 4,2)
37. Lee YK, Sala L, Mura M, Rocchetti M, Pedrazzini M, Ran X, Mak TSH, Crotti L, Sham PC, Torre E, Zaza A, Schwartz PJ, Tse HF, **Gnecchi M**.
MTMR4 SNVs Modulate Ion Channel Degradation and Clinical Severity in Congenital Long QT Syndrome: Insights in the Mechanism of Action of Protective Modifier Genes.
Cardiovasc Res 2020 Mar 16;cvaa019. doi: 10.1093/cvr/cvaa019. Online ahead of print. (IF: 10,8)
38. Ronchi C, Bernardi J, Mura M, Stefanello M, Badone B, Rocchetti M, Crotti L, Brink P, Schwartz PJ, **Gnecchi M***, Zaza A.
NOS1AP Polymorphisms Reduce NOS1 Activity and Interact With Prolonged Repolarization in Arrhythmogenesis.
Cardiovasc Res 2020 Feb 15;cvaa036. doi: 10.1093/cvr/cvaa036. Online ahead of print.
*Corresponding author (IF: 10,8)

39. Gallone G, Angelini F, Fortuni F, **Gnecchi M**, De Filippo O, Baldetti L, Giannini F, Colombo A, D'Ascenzo F, De Ferrari GM.
Angiography- Versus Physiology-Guided Complete Revascularization in Patients With STEMI and Multivessel Disease: Who's the Better Gatekeeper in This Setting?
Eur Heart J Qual Care Clin Outcomes 2020 Feb 3;qcaa007. doi: 10.1093/ehjqcco/qcaa007. (IF: 2,4)
40. Mandurino-Mirizzi A, Demarchi A, Ruffinazzi M, Cornara S, Somaschini A, Crimi G, Ferlini M, Camporotondo R, **Gnecchi M**, Ferrario M, Oltrona Visconti L, De Ferrari GM.
Serum Uric Acid May Modulate the Inflammatory Response After Primary Percutaneous Coronary Intervention in Patients With ST-elevation Myocardial Infarction.
J Cardiovasc Med (Hagerstown) 2020 Apr;21(4):337-339. (IF: 1,3)
41. Somaschini A, Cornara S, Demarchi A, Mandurino-Mirizzi A, Baldi E, Ferlini M, Crimi G, Camporotondo R, **Gnecchi M**, Oltrona Visconti L, De Ferrari GM.
The Unfavourable Inflammatory Response in Elderly Patients After Myocardial Infarction: Should We Talk of 'Dysflaming'?
J Cardiovasc Med (Hagerstown) 2020 Apr;21(4):340-342. (IF: 1,3)
42. De Ferrari GM, Dusi V, Ruffinazzi M, Masiello LC, Ruffino E, Cacciavillani L, Noussan P, Zacà V, Sanna T, Lazzarotti ML, Usmiani T, **Gnecchi M**, Parati G, Crotti L, Schwartz PJ; ESCAPE-NET Investigators.
Risk Factors for Primary Ventricular Fibrillation During a First Myocardial Infarction: Clinical Findings From PREDESTINATION (PRimary vEntricular Fibrillation and suDden dEath During firST myocardial iNfArcTION).
Int J Cardiol 2020 Mar 1;302:164-170. doi: 10.1016/j.ijcard.2019.10.060. (IF: 4,1)
43. Somaschini A, Cornara S, Ferlini M, Crimi G, Camporotondo R, **Gnecchi M**, Ferrario Ormezzano M, Oltrona Visconti L, De Ferrari GM, De Servi S.
Favorable effect of glycoprotein IIb/IIIa inhibitors among STEMI patients treated with primary PCI and incomplete ST resolution.
Platelets. 2020;31(1):48-54. doi: 10.1080/09537104.2018.1562171. (IF: 3,2)
44. Somaschini A, Cornara S, Demarchi A, Mandurino-Mirizzi A, Fortuni F, Crimi G, Ferlini M, Camporotondo R, **Gnecchi M**, Visconti LO, De Ferrari GM.
Neutrophil to Platelet Ratio: A Novel Prognostic Biomarker in ST-elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention.
Eur J Prev Cardiol 2019 Dec 16;2047487319894103. doi: 10.1177/2047487319894103. (IF: 5,8)
45. Mura M, Bastaroli F, Corli M, Ginevrino M, Calabrò F, Boni M, Crotti L, Valente EM, Schwartz PJ, **Gnecchi M**.
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi006-A from a patient affected by an autosomal recessive form of long QT syndrome type 1.
Stem Cell Res. 2019 Nov 20;42:101658. doi: 10.1016/j.scr.2019.101658. (IF: 4,5)

46. Chokoza C, Gustafsson CA, Goetsch KP, Zilla P, Thierfelder N, Pisano F, Mura M, **Gnecchi M**, Bezuidenhout D, Davies NH.
Tuning Tissue Ingrowth into Proangiogenic Hydrogels via Dual Modality Degradation.
ACS Biomater Sci Eng. 2019 Oct 14;5(10):5430-5438. doi: 10.1021/acsbiomaterials.9b01220. (IF: 1,2)
47. Mura M, Pisano F, Stefanello M, Ginevrino M, Boni M, Calabrò F, Crotti L, Valente EM, Schwartz PJ, Brink PA, **Gnecchi M**.
Generation of two human induced pluripotent stem cell (hiPSC) lines from a long QT syndrome South African founder population.
Stem Cell Res. 2019 Aug;39:101510. doi: 10.1016/j.scr.2019.101510. (IF: 4,5)
48. Fortuni F, Crimi G, Angelini F, Leonardi S, D'Ascenzo F, Ferlini M, Rolando M, Raisaro A, Oltrona Visconti L, Ferrario M, **Gnecchi M**, De Ferrari GM.
Early Complete Revascularization in Hemodynamically Stable Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease.
Can J Cardiol. 2019 Aug;35(8):1047-1057. doi: 10.1016/j.cjca.2019.03.006. (IF: 5,2)
49. Sala L, **Gnecchi M**, Schwartz PJ.
Long QT Syndrome Modelling with Cardiomyocytes Derived from Human-induced Pluripotent Stem Cells.
Arrhythm Electrophysiol Rev. 2019 May;8(2):105-110. doi: 10.15420/aer.2019.1.1. (IF: 1,8)
50. Mura M, Lee YK, Pisano F, Ginevrino M, Boni M, Calabrò F, Crotti L, Valente EM, Schwartz PJ, Tse HF, **Gnecchi M**.
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation.
Stem Cell Res. 2019 May;37:101437. doi: 10.1016/j.scr.2019.101437. (IF: 4,5)
51. Mura M, Lee YK, Pisano F, Ginevrino M, Boni M, Calabrò F, Crotti L, Valente EM, Schwartz PJ, Tse HF, **Gnecchi M**.
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation.
Stem Cell Res. 2019 May;37:101431. doi: 10.1016/j.scr.2019.101431. (IF: 4,5)
52. Somaschini A, Demarchi A, Cornara S, Mandurino Mirizzi A, Crimi G, Ferlini M, **Gnecchi M**, Camporotondo R, Oltrona Visconti L, Ferrario Ormezzano M, De Ferrari GM.
Smoker's paradox in ST-elevation myocardial infarction: Role of inflammation and platelets.
Hellenic J Cardiol. 2019 Apr 2. pii: S1109-9666(19)30068-5. doi: 10.1016/j.hjc.2019.03.004. (IF: 4)
53. Mura M, Pisano F, Stefanello M, Ginevrino M, Boni M, Calabrò F, Crotti L, Valente EM, Schwartz PJ, Brink PA, **Gnecchi M**.
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene.
Stem Cell Res. 2019 Apr;36:101416. doi: 10.1016/j.scr.2019.101416. (IF: 4,5)

54. Schwartz PJ*, **Gnecchi M***, Dagradi F, Castelletti S, Parati G, Spazzolini C, Sala L, Crotti L*.
**Corresponding author*
From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2.
 Eur Heart J. 2019 Jun 14;40(23):1832-1836. doi: 10.1093/eurheartj/ehz023. (IF: 22,6)
55. Wagner T, Traxler D, Simader E, Beer L, Narzt MS, Gruber F, Madlener S, Laggner M, Erb M, Vorstandlechner V, Gugerell A, Radtke C, **Gnecchi M**, Peterbauer A, Gschwandtner M, Tschachler E, Keibl C, Slezak P, Ankersmit HJ, Mildner M.
Different pro-angiogenic potential of γ -irradiated PBMC-derived secretome and its subfractions.
 Sci Rep. 2018 Dec 20;8(1):18016. doi: 10.1038/s41598-018-36928-6. (IF: 4)
56. **Gnecchi M.**
Cell Therapy for Heart Regeneration: Learning from the Past to Build a Brighter Future.
 Stem Cells Transl Med. 2018 Oct;7(10):702-704. doi: 10.1002/sctm.18-0126. (IF: 5,9)
57. Mura M, Ginevrino M, Zappatore R, Pisano F, Boni M, Castelletti S, Crotti L, Valente EM, Schwartz PJ, **Gnecchi M.**
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1.
 Stem Cell Res. 2018 May;29:170-173. doi: 10.1016/j.scr.2018.04.003.(IF: 3,9)
58. Mura M, Lee YK, Ginevrino M, Zappatore R, Pisano F, Boni M, Dagradi F, Crotti L, Valente EM, Schwartz PJ, Tse HF, **Gnecchi M.**
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene.
 Stem Cell Res. 2018 May; 29:157-161. doi: 10.1016/j.scr.2018.04.002. (IF: 3,9)
59. Ciuffreda MC, Malpasso G, Chokoza C, Bezuidenhout D, Goetsch KP, Mura M, Pisano F, Davies NH, **Gnecchi M.**
Synthetic extracellular matrix mimic hydrogel improves efficacy of mesenchymal stromal cell therapy for ischemic cardiomyopathy.
 Acta Biomater. 2018 Jan 13. pii: S1742-7061(18)30016-3. doi: 10.1016/j.actbio.2018.01.005. (IF: 7)
60. Pisano F, Mura M, Ciuffreda MC, Calabrò F, Lanzo N, **Gnecchi M.**
Optimized lentiviral transduction of human amniotic mesenchymal stromal cells.
 Pharmacol Res. 2018 Jan;127:49-57. doi: 10.1016/j.phrs.2017.11.014. (IF: 5,6)
61. Mehta A, Ramachandra CJA, Singh P, Chitre A, Lua CH, Mura M, Crotti L, Wong P, Schwartz PJ, **Gnecchi M***, Shim W. **Corresponding author*
Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model.
 European Heart Journal July 2017 (Fast Track Paper) <https://doi.org/10.1093/eurheartj/ehx394>. (IF= 20,2)

62. Cornara S, Somaschini A, De Servi S, Crimi G, Ferlini M, Baldo A, Camporotondo R, **Gnecchi M**, Ferrario Ormezzano M, Oltrona Visconti L, De Ferrari GM.
Prognostic Impact of in-Hospital-Bleeding in Patients With ST-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention.
Am J Cardiol. 2017 Nov 15;120(10):1734-1741. doi: 10.1016/j.amjcard.2017.07.076. (IF= 3,4)
63. Imperlini E, **Gnecchi M**, Rognoni P, SabidV≤ E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M, Malpasso G, Valentini V, Palladini G, Orrvπ S, Ferraro G, Milani P, Perlini S, Salvatore F, Merlini G, Lavatelli F.
Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
Sci Rep. 2017 Nov 15;7(1):15661. doi: 10.1038/s41598-017-15424-3. (IF= 4,25)
64. Mura M, Mehta A, Ramachandra CJ, Zappatore R, Pisano F, Ciuffreda MC, Barbaccia V, Crotti L, Schwartz PJ, Shim W, **Gnecchi M**.
The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2.
Int J Cardiol. 2017 Aug 1;240:367-371. doi: 10.1016/j.ijcard.2017.04.038.(IF= 4,6)
65. **Gnecchi M**, Stefanello M, Mura M.
Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias.
Int J Cardiol. 2017 Jun 15;237:49-52. doi: 10.1016/j.ijcard.2017.03.085. (IF= 4,6)
66. Rocchetti M, Sala L, Dreizehnter L, Crotti L, Sinnecker D, Mura M, Pane LS, Altomare C, Torre E, Mostacciolo G, Severi S, Porta A, De Ferrari GM, George AL Jr, Schwartz PJ, **Gnecchi M**, Moretti A, Zaza A.
Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Cardiovasc Res. 2017 Apr 1;113(5):531-541. doi: 10.1093/cvr/cvx006. (IF= 5,5)
67. Marino M, Crimi G, Leonardi S, Ferlini M, Repetto A, Camporotondo R, Demarchi A, De Pascali I, Falcinella F, Oltrona Visconti L, De Servi S, Ferrario M, De Ferrari GM, **Gnecchi M**.
Comparison of Outcomes of Staged Complete Revascularization Versus Culprit Lesion-Only Revascularization for ST-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease.
Am J Cardiol. 2017 Feb 15;119(4):508-514. doi: 10.1016/j.amjcard.2016.10.040. (IF= 3,1)
68. Danieli P, Malpasso G, Ciuffreda MC, **Gnecchi M**.
Testing the Paracrine Properties of Human Mesenchymal Stem Cells Using Conditioned Medium.
Methods Mol Biol. 2016;1416:445-56. doi: 10.1007/978-1-4939-3584-0_26. (IF= 1)
69. Ciuffreda MC, Malpasso G, Musarò P, Turco V, **Gnecchi M**.
Protocols for in vitro Differentiation of Human Mesenchymal Stem Cells into Osteogenic, Chondrogenic and Adipogenic Lineages.
Methods Mol Biol. 2016;1416:149-58. doi: 10.1007/978-1-4939-3584-0_8. (IF= 1)

70. Pisano F, **Gnecchi M**.
Transfection of Embryoid bodies with miRNA precursors to induce cardiac differentiation.
Bio Protocols. 2016; vol 6, iss3. doi: <http://doi.org/10.21769/BioProtoc.1726>
71. **Gnecchi M**, Danieli P, Malpasso G, Ciuffreda MC.
Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair.
Methods Mol Biol. 2016;1416:123-46. doi: [10.1007/978-1-4939-3584-0_7](https://doi.org/10.1007/978-1-4939-3584-0_7). (IF= 1)
72. **Gnecchi M**, Pisano F, Bariani R.
microRNA and Cardiac Regeneration.
Adv Exp Med Biol. 2015;887:119-41. doi: [10.1007/978-3-319-22380-3_7](https://doi.org/10.1007/978-3-319-22380-3_7). (IF= 1,9)
73. Danieli P, Malpasso G, Ciuffreda MC, Cervio E, Calvillo L, Copes F, Pisano F, Mura M, Kleijn L, de Boer R, Viarengo G, Rosti V, Spinillo A, Roccio M, **Gnecchi M**.
Conditioned medium from human amniotic mesenchymal stromal cells limits infarct size and enhances angiogenesis.
Stem Cells Transl Med. 2015 May;4(5):448-58. doi: [10.5966/sctm.2014-0253](https://doi.org/10.5966/sctm.2014-0253). (IF= 4,2)
74. Lavatelli F, Imperlini E, Orrù S, Rognoni P, Sarnataro D, Palladini G, Malpasso G, Soriano ME, Di Fonzo A, Valentini V, **Gnecchi M**, Perlini S, Salvatore F, Merlini G.
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.
FASEB J. 2015 Nov;29(11):4614-28. doi: [10.1096/fj.15-272179](https://doi.org/10.1096/fj.15-272179). (IF= 5,3)
75. Yulyana Y, Ho IA, Sia KC, Newman JP, Toh XY, Endaya BB, Chan JK, **Gnecchi M**, Huynh H, Chung AY, Lim KH, Leong HS, Iyer NG, Hui KM, Lam PY.
Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.
Mol Ther. 2015 Apr;23(4):746-56. doi: [10.1038/mt.2015.13](https://doi.org/10.1038/mt.2015.13). (IF= 6,9)
76. Pisano F, Altomare C, Cervio E, Barile L, Rocchetti M, Ciuffreda MC, Malpasso G, Copes F, Manuela M, Patrizia D, Viarengo G, Zaza A, **Gnecchi M**.
Combination of miRNA499 and miRNA133 exerts a synergic effect on cardiac differentiation.
Stem Cells. 2015 Apr;33(4):1187-99. doi: [10.1002/stem.1928](https://doi.org/10.1002/stem.1928). (IF= 6,5)
77. Ciuffreda MC, Tolva V, Casana R, **Gnecchi M**, Vanoli E, Spazzolini C, Roughan J, Calvillo L.
Rat experimental model of myocardial ischemia/reperfusion injury: an ethical approach to set up the analgesic management of acute post-surgical pain.
PLoS One. 2014;9(4):e95913. doi: [10.1371/journal.pone.0095913](https://doi.org/10.1371/journal.pone.0095913). (IF= 3,2)
78. Perotti C, Arici V, Cervio M, Del Fante C, Calliada F, **Gnecchi M**, Ciuffreda MC, Scudeller L, Bozzani A, Ragni F, Viarengo G, Cervio E, Odero A, Redi CA.
Allogeneic lethally irradiated cord blood mononuclear cells in no-option critical limb ischemia: A "Box of Rain".
Stem Cells Dev. 2013;22(20):2806-12. doi:[10.1089/scd.2013.0172](https://doi.org/10.1089/scd.2013.0172). (IF= 4,2)

79. **Gnecchi M**, Schwartz PJ.
The unstoppable attraction for induced pluripotent stem cells: are they the magic bullet for modeling inherited arrhythmogenic diseases?
J Am Coll Cardiol. 2012; 60(11):1001-4. doi: 10.1016/j.jacc.2012.04.019. (IF= 14,1)
80. **Gnecchi M**, Danieli P, Cervio E.
Mesenchymal stem cell therapy for heart disease.
Vascul Pharmacol. 2012; 57(1):48-55. doi: 10.1016/j.vph.2012.04.002. (IF= 3,2)
81. Calvillo L, Vanoli E, Andreoli E, Besana A, Omodeo E, **Gnecchi M**, Zerbi P, Vago G, Busca G, Schwartz PJ. Vagal stimulation.
Through its nicotinic action, limits infarct size and the inflammatory response to ischemia and reperfusion.
J Cardiovasc Pharmacol. 2011; 58:500-7. doi: 10.1097/FJC.0b013e31822b7204. (IF= 2,3)
82. Mirotso M, Jayawardena TM, Schmeckpeper J, **Gnecchi M**, Dzau VJ.
Paracrine mechanisms of stem cell reparative and regenerative actions in the heart.
J Mol Cell Cardiol. 2011; 50:280-9. doi: 10.1016/j.yjmcc.2010.08.005. (IF= 5)
83. **Gnecchi M**, He H, Melo LG, Noiseux N, Morello F, de Boer RA, Zhang L, Pratt RE, Dzau VJ, Ingwall JS.
Early beneficial effects of bone marrow derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction.
Stem Cells 2009; 27:971-979. doi: 10.1002/stem.12. (IF= 7,5)
84. **Gnecchi M**, Melo LG.
Bone Marrow-Derived Mesenchymal Stem Cells: Isolation, Expansion, Characterization, Viral Transduction and Conditioned Media Production.
Methods Mol Biol. 2009;482:281-94. doi: 10.1007/978-1-59745-060-7_18. (IF= 1)
85. **Gnecchi M**, Zhang Z, Ni A, Dzau VJ.
Paracrine mechanisms in adult stem cell signaling and therapy.
Circ Res. 2008; 103:1204-1219. doi: 10.1161/CIRCRESAHA.108.176826. (IF= 9,7)
86. Mirotso M, Zhang Z, Deb A, Zhang L, **Gnecchi M**, Noiseux N, Mu H, Pachori A, Dzau V.
Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair.
Proc Natl Acad Sci U S A. 2007; 104:1643-8. doi:10.1073/pnas.0610024104 (IF= 9,6)
87. **Gnecchi M**, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ.
Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell mediated cardiac repair and functional improvement.
FASEB J. 2006; 20:661-9. doi: 10.1096/fj.05-5211com (IF= 6,8)

88. Liu X, Pachori A, Ward CA, Davis JP, **Gnecchi M**, Kong D, Zhang L, Murduck J, Yet SF, Perrella MA, Pratt RE, Dzau VJ, Melo LG.
Heme oxygenase-1 (HO-1) inhibits post myocardial infarction remodeling and restores ventricular function.
FASEB J. 2006; 20:207-16. doi: 10.1096/fj.05-4435com. (IF= 6,8)
89. Noiseux N, **Gnecchi M**, Lopez-Illasaca M, Zhang L, Solomon SD, Deb A, Dzau VJ, Pratt RE.
Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation.
Molecular Therapy 2006; 14:840-50. doi:10.1016/j.ymthe.2006.05.016 (IF= 5,9)
90. Dzau VJ, Pachori A, **Gnecchi M**.
Enhancing stem cell therapy efficacy through genetic modification.
J Am Coll Cardiol. 2005; 46:1351-3. (IF= 11)
91. Morello F, de Boer RA, Steffensen KR, **Gnecchi M**, Chisholm JW, Anderson LM, Lawn RM, Gustafsson JA, Lopez-Illasaca M, Pratt RE, Dzau VJ.
Liver X receptors α and β are in vivo pathophysiological regulators of renin.
Journal of Clinical Investigation 2005; 115:1913-22. (IF= 16,9)
92. Dzau VJ, **Gnecchi M**, Pachori A, Melo LG.
Therapeutic potential of endothelial progenitor cells in cardiovascular diseases.
Hypertension 2005; 46:7-18. (IF= 7,2)
93. Melo LG, Pachori AS, **Gnecchi M**, Dzau VJ.
Genetic therapies for cardiovascular diseases: where we are and where we are going.
Trends Mol Med. 2005; 11(5):240-50. doi.org/10.1016/j.molmed.2005.03.008 (IF= 7,2)
94. **Gnecchi M**, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ.
Paracrine action accounts for marked protection of ischemic heart by AKT modified mesenchymal stem cells.
Nature Medicine 2005; 11(4):367-8. (IF= 26,4)
95. Kong D, Melo LG, **Gnecchi M**, Zhang L, Mostoslavsky G, Liew CC, Pratt RE, Dzau VJ.
Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries.
Circulation 2004; 110(14):2039-46. (IF= 12,7)
96. Melo LG, **Gnecchi M**, Pachori AS, Kong D, Wang K, Liu X, Pratt RE, Dzau VJ.
Endothelium Targeted gene and cell-based therapies for vascular diseases.
Arteriosclerosis, thrombosis, and vascular biology 2004; 24(10):1761-74. (IF= 7,2)

97. Melo LG, Pachori AS, Kong D, **Gnecchi M**, Wang K, Pratt RE, Dzau VJ.
Molecular and cell based therapies for protection, rescue and repair of ischemic myocardium: Reasons for cautious optimism.
Circulation 2004; 109 (20):2386-2393. (IF= 12,7)
98. Melo LG, Pachori AS, Kong D, **Gnecchi M**, Wang K, Pratt RE, Dzau VJ.
Gene and cell-based therapies for heart disease.
FASEB Journal 2004; 18(6):648-663. (IF= 6,7)
99. Canosi U, Angelica Merlini P, Bernardi F, Repetto A, Bramucci E, Ferrario M, Angoli L, **Gnecchi M**, Ferraresi P, Marchetti G, Tavazzi L, Ardissino D.
Angiotensin-converting enzyme insertion/deletion polymorphism and risk of restenosis after directional coronary atherectomy followed by stent implantation.
Thrombosis and Hemostasis 2004; 91(4):795-800. (IF= 3,5)
100. Melo LG, **Gnecchi M**, Pachori AS, Wang K, Dzau VJ.
Gene and cell-based therapies for cardiovascular diseases: current status and future directions.
European Heart Journal Supplement 2004; 6:E24-E35. (IF= 1,6)
101. Bramucci E, Repetto A, Ferrario M, Canosi U, Boschetti E, Brambilla N, **Gnecchi M**, Merlini PA, Ardissino D, Angoli L, Tavazzi L.
Effectiveness of adjunctive stent implantation following directional coronary atherectomy for treatment of left anterior descending ostial stenosis.
Am J Cardiol. 2002; 90(10):1074-8. (IF= 3,6)

Pavia, 6 June 2024